악성뚜렛 증후군의 치료대안

키워드

참고문헌 (69)

1. Robertson MM, "The international prevalence, epidemiology, and clinical phenomenology of Tourette syndrome: a cross-cultural perspective", J Psychosom Res, 67, pp.475~483 (2009)
2. Bloch MH, "Adulthood outcome of tic and obsessivecompulsive symptom severity in children with Tourette syndrome", Arch Pediatr Adolesc Med, 160, pp.65~69 (2006)
3. Leckman JF, "Course of tic severity in Tourette syndrome: the first two decades", Pediatrics, 102, pp.14~19 (1998)
4. Cheung MY, "Malignant Tourette syndrome", Mov Disord, 22, pp.1743~1750 (2007)
5. Singer HS., "Tourette’s syndrome: from behaviour to biology", Lancet Neurol, 4, pp.149~159 (2005)
6. Gerard E, "Developmental processes and brain imaging studies in Tourette syndrome", J Psychosom Res, 55, pp.13~22 (2003)
7. Peterson BS, "Corpus callosum morphology from magnetic resonance images in Tourette’s syndrome", Psychiatry Res, 55, pp.85~99 (1994)
8. Albin RL, "Recent advances in Tourette syndrome research", Trends Neurosci, 29, pp.175~182 (2006)
9. Leckman JF, "Annotation: Tourette syndrome: a relentless drumbeat-- driven by misguided brain oscillations", J Child Psychol Psychiatry, 47, pp.537~550 (2006)
10. Kalanithi PS, "Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome", Proc Natl Acad Sci U S A, 102, pp.13307~13312 (2005)
11. Peterson BS, "A functional magnetic resonance imaging study of tic suppression in Tourette syndrome", Arch Gen Psychiatry, 55, pp.326~333 (1998)
12. Gates L, "Neuroanatomy of coprolalia in Tourette syndrome using functional magnetic resonance imaging", Prog Neuropsychopharmacol Biol Psychiatry, 28, pp.397~400 (2004)
13. Kawohl W, "Functional magnetic resonance imaging of tics and tic suppression in Gilles de la Tourette syndrome", World J Biol Psychiatry, 10, pp.567~570 (2009)
14. Stern E, "Trimble M, et al. A functional neuroanatomy of tics in Tourette syndrome", Arch Gen Psychiatry, 57, pp.741~748 (2000)
15. Singer HS, "Volumetric MRI changes in basal ganglia of children with Tourette’s syndrome", Neurology, 43, pp.950~956 (1993)
16. Peterson BS, "Basal Ganglia volumes in patients with Gilles de la Tourette syndrome", Arch Gen Psychiatry, 60, pp.415~424 (2003)
17. Bloch MH, "Caudate volumes in childhood predict symptom severity in adults with Tourette syndrome", Neurology, 65, pp.1253~1258 (2005)
18. Leckman JF, "Tourette’s syndrome", Lancet, 360, pp.1577~1586 (2002)
19. Silva RR, "Environmental factors and related fluctuation of symptoms in children and adolescents with Tourette’s disorder", J Child Psychol Psychiatry, 36, pp.305~312 (1995)
20. Hoekstra PJ, "Neurobiology and neuroimmunology of Tourette’s syndrome: an update", Cell Mol Life Sci, 61, pp.886~898 (2004)
21. Martino D, "Autoaggressive immune-mediated movement disorders", Adv Neurol, 96, pp.320~335 (2005)
22. Church AJ, "Anti-basal ganglia antibodies: a possible diagnostic utility in idiopathic movement disorders?", Arch Dis Child, 89, pp.611~614 (2004)
23. Morer A, "D8", 17 monoclonal antibody: an unclear neuropsychiatric marker, 2005, pp.16, 1~8
24. Denys D, "Decreased TNF-alpha and NK activity in obsessive-compulsive disorder", Psychoneuroendocrinology, 29, pp.945~952 (2004)
25. Leckman JF, "Increased serum levels of interleukin-12 and tumor necrosis factor-alpha in Tourette’s syndrome", Biol Psychiatry, 57, pp.667~673 (2005)
26. Martino D, "Soluble adhesion molecules in Gilles de la Tourette’s syndrome", J Neurol Sci, 234, pp.79~85 (2005)
27. Seo WS, "Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder", JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 18, pp.197~205, AACAP
28. 박수빈, "An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders", JOURNAL OF CLINICAL PSYCHIATRY, 68(7), pp.1088~1093, PHYSICIANS POSTGRADUATE PRESS
29. Porta M, "Tourette’s syndrome and role of tetrabenazine: review and personal experience", Clin Drug Investig, 28, pp.443~459 (2008)
30. Zheng G, "Vesicular monoamine transporter 2: role as a novel target for drug development", AAPS J, 8, pp.682~692 (2006)
31. Ondo WG, "Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol", Am J Psychiatry, 156, pp.1279~1281 (1999)
32. Huntington Study Group, "Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial", Neurology, 66, pp.366~372 (2006)
33. Kenney C, "Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders", Mov Disord, 22, pp.193~197 (2007)
34. Jankovic J, "Long-term effects of tetrabenazine in hyperkinetic movement disorders", Neurology, 48, pp.358~362 (1997)
35. Jankovic J, "Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias", Neurology, 38, pp.391~394 (1988)
36. Paleacu D, "Tetrabenazine treatment in movement disorders", Clin Neuropharmacol, 27, pp.230~233 (2004)
37. Mikkelsen BO, "Tolerance of tetrabenazine during long-term treatment", Acta Neurol Scand, 68, pp.57~60 (1983)
38. Ossemann M, "Tetrabenazine as a cause of neuroleptic malignant syndrome", Mov Disord, 11, pp.95~ (1996)
39. Singer HS, "Haloperidol, fluphenazine and clonidine in Tourette syndrome: controversies in treatment", Pediatr Neurosci, 12, pp.71~74 (1985)
40. Leckman JF, "Clonidine in the treatment of Tourette syndrome: a review of data", Adv Neurol, 35, pp.391~401 (1982)
41. Leckman JF, "Short- and long-term treatment of Tourette’s syndrome with clonidine: a clinical perspective", Neurology, 35, pp.343~351 (1985)
42. Hedderick EF, "Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome", Pediatr Neurol, 40, pp.420~425 (2009)
43. Scahill L, "Contemporary assessment and pharmacotherapy of Tourette syndrome", NeuroRx, 3, pp.192~206 (2006)
44. Bloch MH, "Meta-analysis: treatment of attention-deficit", hyperactivity disorder in children with comorbid tic disorders, 2009, pp.48, 884~893
45. Chappell PB, "Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette’s syndrome: preliminary clinical experience", J Am Acad Child Adolesc Psychiatry, 34, pp.1140~1146 (1995)
46. Gilbert DL, "Tic reduction with pergolide in a randomized controlled trial in children", Neurology, 60, pp.606~611 (2003)
47. Gilbert DL, "Tourette’s syndrome improvement with pergolide in a randomized, double-blind, crossover trial", Neurology, 54, pp.1310~1315 (2000)
48. Arnone D., "Review of the use of Topiramate for treatment of psychiatric disorders", Ann Gen Psychiatry, 4(5) (2005)
49. Jankovic J, "A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome", J Neurol Neurosurg Psychiatry, 81, pp.70~73 (2010)
50. Kuo SH, "Topiramate in treatment of tourette syndrome", Clin Neuropharmacol, 33, pp.32~34 (2010)
51. Awaad Y, "Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome", Mov Disord, 20, pp.714~718 (2005)
52. Smith-Hicks CL, "A double blind randomized placebo control trial of levetiracetam in Tourette syndrome", Mov Disord, 22, pp.1764~1770 (2007)
53. Jankovic J., "Botulinum toxin in the treatment of dystonic tics", Mov Disord, 9, pp.347~349 (1994)
54. Kwak CH, "Botulinum toxin in the treatment of tics", Arch Neurol, 57, pp.1190~1193 (2000)
55. Marras C, "Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial", Neurology, 56, pp.605~610 (2001)
56. Porta M, "Treatment of phonic tics in patients with Tourette’s syndrome using botulinum toxin type A", Neurol Sci, 24, pp.420~423 (2004)
57. Rapoport M, "Response of major depression and Tourette’s syndrome to ECT: a case report", Psychosom Med, 60, pp.528~529 (1998)
58. Bloch MH., "Emerging treatments for Tourette’s disorder", Curr Psychiatry Rep, 10, pp.323~330 (2008)
59. Fink M, "Catatonia: A clinician’s guide to diagnosis and treatment" (2003), Oxford University Press
60. Swerdlow NR, "Electroconvulsive therapy in a patient with severe tic and major depressive episode", J Clin Psychiatry, 51, pp.34~35 (1990)
61. Strassnig M, "Electroconvulsive therapy in a patient with Tourette’s syndrome and comorbid Obsessive Compulsive Disorder", World J Biol Psychiatry, 5, pp.164~166 (2004)
62. Dehning S, "Longterm results of electroconvulsive therapy in severe Gilles de la Tourette syndrome", J ECT, 27, pp.145~147 (2011)
63. Mantovani A, "Repetitive Transcranial Magnetic Stimulation of the Supplementary Motor Area in the treatment of Tourette Syndrome: report of two cases", Clin Neurophysiol, 118, pp.2314~2315 (2007)
64. Mantovani A, "Repetitive transcranial magnetic stimulation(rTMS) in the treatment of obsessive-compulsive disorder(OCD) and Tourette’s syndrome(TS)", Int J Neuropsychopharmacol, 9, pp.95~100 (2006)
65. Porta M, "Thalamic deep brain stimulation for treatment-refractory Tourette syndrome: two-year outcome", Neurology, 73, pp.1375~1380 (2009)
66. Vandewalle V, "Stereotactic treatment of Gilles de la Tourette syndrome by high frequency stimulation of thalamus", Lancet, 353, pp.724~ (1999)
67. Servello D, "Deep brain stimulation in 18 patients with severe Gilles de la Tourette syndrome refractory to treatment: the surgery and stimulation", J Neurol Neurosurg Psychiatry, 79, pp.136~142 (2008)
68. Ackermans L, "Double-blind clinical trial of thalamic stimulation in patients with Tourette syndrome", Brain, 134, pp.832~844 (2011)
69. Kurlan R., "Clinical practice. Tourette’s Syndrome", N Engl J Med, 363, pp.2332~2338 (2010)

관련 논문AI추천